AstraZeneca inked a five-year research deal with Harvard Stem Cell Institute (HSCI) for new treatments for diabetes. The company announced today that it has entered into a five-year research collaboration with HSCI to adapt a technique that creates human beta cells from stem cells for use in screens for AstraZeneca’s …
Tag Archives: Semma Therapeutics
March, 2015
-
24 March
Semma Secures $44 Million and Partners with Novartis for Diabetes Stem Cell Therapy
New diabetes biotech startup, working on a stem cell technology that could potentially reverse the cause of Type 1 diabetes, has picked up $44 million in funding, and entered into a deal with Novartis Pharmaceuticals. Semma Therapeutics announced Tuesday that it has closed a $44 million Series A consisting of …